New Mexico § 24-2C-5 Program

New Mexico Statutes

§ 24-2C-5 — Program

New Mexico § 24-2C-5

Ch. 24Health and Safety

Art. 2CHarm Reduction

This text of New Mexico § 24-2C-5 (Program) is published on Counsel Stack Legal Research, covering New Mexico primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook

N.M. Stat. Ann. § 24-2C-5 (2026).

Text

The harm reduction program shall provide participants with: A. sterile hypodermic syringes and needles in exchange for used hypodermic syringes, needles or other objects used to inject controlled substances or controlled substance analogs into the human body; B. other objects used to prepare or consume controlled substances or controlled substance analogs; C. supplies or devices used for testing controlled substances or controlled substance analogs for potentially dangerous adulterants; D. supplies or devices approved by the department for distribution in accordance with rules established pursuant to Subsection E of Section 24-2C-4 NMSA 1978; E. education on the prevention of:

(1)the transmission of the human immunodeficiency virus and hepatitis B and C; and (2) drug overdose mortality an

Free access — add to your briefcase to read the full text and ask questions with AI

The harm reduction program shall provide participants with: A. sterile hypodermic syringes and needles in exchange for used hypodermic syringes, needles or other objects used to inject controlled substances or controlled substance analogs into the human body; B. other objects used to prepare or consume controlled substances or controlled substance analogs; C. supplies or devices used for testing controlled substances or controlled substance analogs for potentially dangerous adulterants; D. supplies or devices approved by the department for distribution in accordance with rules established pursuant to Subsection E of Section 24-2C-4 NMSA 1978; E. education on the prevention of: (1) the transmission of the human immunodeficiency virus and hepatitis B and C; and (2) drug overdose mortality and other negative health outcomes; and F. referral to substance abuse treatment services.